Vimian Group ABVIMGF 75 Days Payable is 58.12 as of Mar. 2026, which is 25% below its 10-year median of 77.07. GuruFocus rates VIMGF with a GF Score™ of 75/100 and a GF Value™ of $3.24. The stock has 2 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 54.45% on this metric.
The historical rank and industry rank for Vimian Group AB's Days Payable or its related term are showing as below:
VIMGF'
s Days Payable Range Over the Past 10 Years
Min: 59.56 Med: 77.07 Max: 184.58
Current: 61.43
During the past 9 years, Vimian Group AB's highest Days Payable was 184.58. The lowest was 59.56. And the median was 77.07.
VIMGF's Days Payable is ranked worse than 54.45% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs VIMGF: 61.43
Vimian Group AB's Days Payable
declined
from Mar. 2025 (67.83) to Mar. 2026 (58.12).
It may suggest that Vimian Group ABaccelerated paying its suppliers.
Vimian Group AB Days Payable Related Terms
Vimian Group AB Days Payable Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vimian Group AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a Days Payable of 58.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vimian Group AB and its competitors. This is 25% below median its historical median of 77.07. Over the past decade, Vimian Group AB's Days Payable has ranged from 59.56 to 184.58. According to the industry distribution chart, Vimian Group AB ranks #104 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 54.5%.
Is Vimian Group AB's Days Payable too high?
Vimian Group AB's current Days Payable of 58.12 is 25% below median its 10-year median of 77.07. Over the past 10 years, this metric has ranged from a low of 59.56 to a high of 184.58. The Medical Diagnostics & Research industry median Days Payable is 68.87. Vimian Group AB's value of 58.12 is 15.6% below this industry median. Based on the distribution chart, Vimian Group AB ranks #104 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #104 out of 191 companies for Days Payable. This places Vimian Group AB in the lower half of its industry. The industry median Days Payable is 68.87. Vimian Group AB's value of 58.12 is 15.6% below this benchmark. Historically, Vimian Group AB's own Days Payable has ranged from 59.56 to 184.58 over the past decade. While the company's 10-year median is 77.07 vs. the industry median of 68.87, Vimian Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current Days Payable of 58.12 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current Days Payable is 58.12, which is 25% below median its own 10-year median of 77.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Days Payable of 58.12. The stock's GF Value™ is $3.24, compared to a current price of $2.77 — trading 14.5% below its estimated fair value. The current Days Payable is 58.12, which is 25% below median its 10-year median of 77.07 and 15.6% below the Medical Diagnostics & Research industry median of 68.87. Vimian Group AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Days Payable is 58.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 14.5% below its estimated GF Value™ of $3.24.
Key valuation signals for VIMGF:
Days Payable: 58.12 (25% below median its 10-year median of 77.07)
GF Value™: $3.24 vs. price of $2.77 (14.5% below fair value)
Industry Position: 15.6% below the Medical Diagnostics & Research median (#104 of 191)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
75GF Score
Get the complete analysis for VIMGF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
